WO2022175852 - METHODS AND COMPOSITIONS FOR DETERMINING SUSCEPTIBILITY TO TREATMENT WITH CHECKPOINT INHIBITOR
National phase entry:
Publication Number
WO/2022/175852
Publication Date
25.08.2022
International Application No.
PCT/IB2022/051399
International Filing Date
17.02.2022
Title **
[English]
METHODS AND COMPOSITIONS FOR DETERMINING SUSCEPTIBILITY TO TREATMENT WITH CHECKPOINT INHIBITOR
[French]
PROCÉDÉS ET COMPOSITIONS POUR DÉTERMINER LA SENSIBILITÉ À UN TRAITEMENT AVEC UN INHIBITEUR DE POINT DE CONTRÔLE
Applicants **
NOVOCURE GMBH
6 Park
6039 Root D4, CH
Inventors
TRAN, David
2230 NW 104th Way
Gainesville, Florida 32606, US
CHEN, Dongjiang
2905 SW Archer Road, Apt. 5024
Gainesville, Florida 32608, US
Priority Data
63/150,359
17.02.2021
US
63/172,862
09.04.2021
US
17/673,602
16.02.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2231 | |
| EPO | Filing, Examination | 11461 | |
| Japan | Filing | 591 | |
| South Korea | Filing | 640 | |
| USA | Filing, Examination | 5160 |
Total: 20083 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Methods and kits treating a subject with a checkpoint inhibitor are provided by detecting expression levels of one or more biomarkers (e.g., cytokines and cytotoxic genes, immune cell functional regulators, naïve immune cell markers, regulatory T cell factors, and immune inhibitory receptors) in immune cells of a patient or subject with a condition (e.g., cancer) before and after exposure of tumor cells to alternating electric fields. Kits comprising nucleic acid probes for detecting the one or more biomarkers are also provided.[French]
L'invention concerne des procédés et des kits pour traiter un sujet avec un inhibiteur de point de contrôle par détection des niveaux d'expression d'un ou de plusieurs biomarqueurs (par exemple, des cytokines et des gènes cytotoxiques, des régulateurs fonctionnels de cellules immunitaires, des marqueurs de cellules immunitaires naïves, des facteurs de lymphocytes T régulateurs et des récepteurs d'inhibition immunitaire) dans des cellules immunitaires d'un patient ou d'un sujet souffrant d'une pathologie (par exemple, un cancer), avant et après exposition de cellules tumorales à des champs électriques alternatifs. L'invention concerne également des kits comprenant des sondes d'acide nucléique pour détecter le ou les biomarqueurs.